

	Erlotinib N=13	Control N=14	p
Median disease-free survival (days)	365	256	0.0001
Number of tumors	19	31	0.0003
ER-positive tumors	14	12	n.s.
ER-negative tumors	5	19	0.0000002
EGFR*			
0	10	3	0.0004
1+	6	8	
2+	0	6	
3+	0	2	
ALDH1* (SD)	3.8% (2.8%)	9.0% (9.8%)	0.11 (n.s.)
Ki67* (SD)	21.4% (14%)	30.4% (17.7 %)	0.6 (n.s.)
Cleaved Caspase 3* (SD)	18.4% (8.6%)	10.6 (8.4%)	0.018

Tab. 1